Home › Pharmacology › Meglitinides (Glinides): Mechanism, Uses and Pharmacokinetics
Meglitinides (Glinides)
Meglitinides
For medical students2 min readUpdated 2026-10-10
Meglitinides, or glinides, are a class of oral hypoglycemic agents that act as regulators of postprandial glycemia. Drugs in this group effectively prevent sharp spikes in blood glucose levels after meals by restoring the early phase of insulin secretion.
Peak actionFirst 15 minutes after a meal
SelectivityHigh affinity for pancreatic beta-cells
AdministrationImmediately before a meal, up to 30 minutes
NateglinidePredominantly renal excretion (83%)
RepaglinideExcreted primarily via bile, approved for renal impairment
Mechanism of Action and Pharmacological Profile
Glinides belong to regulators of blood sugar levels after meals (postprandial glycemia). Their main goal is the prevention and management of postprandial hyperglycemia.
Insulin secretion: the drugs block ATP-sensitive $K^+$ channels in pancreatic $eta$-cells, causing membrane depolarization. This leads to the opening of $Ca^{2+}$ channels and subsequent insulin exocytosis.
Physiological action: unlike sulfonylureas, glinides restore the early, glucose-stimulated phase of insulin release.
Glucose dependency: the agents have a minimal effect on basal secretion. A drop in glucose levels automatically terminates the stimulation of insulin release, minimizing the risk of hypoglycemia if a meal is missed.
Safety: high selectivity for pancreatic channels (exceeding cardiovascular receptors by 300-fold) ensures cardiovascular safety.
Characteristics of Nateglinide
Nateglinide (trade name Starlix) is a phenylalanine amino acid derivative and a prominent representative of meglitinides.
Pharmacokinetics: the drug is rapidly absorbed after oral administration, with a bioavailability of about 72%. Maximum plasma concentration is reached in less than an hour.
Metabolism and excretion: breakdown occurs in the liver via cytochrome P450 isoenzymes, forming active hydroxylated metabolites. The half-life ($T_{1/2}$) is about 1.5 hours, and the drug is excreted predominantly by the kidneys — up to 30% or more, with up to 83% found in urine.
Administration guidelines: the medication is taken orally immediately before a meal, and the interval between taking the pill and starting the meal should not exceed 30 minutes.
Features of Repaglinide
Repaglinide is another important member of the group, derived from benzoic acid and structurally analogous to nateglinide.
Excretion pathways: unlike nateglinide, this drug is eliminated mainly via the bile rather than the kidneys.
Clinical advantage: due to this excretion profile, repaglinide is officially approved for use in patients with concomitant renal impairment.
Pharmacological effect: provides a rapid onset of maximum hypoglycemic action within the first 15 minutes after a meal, effectively controlling glucose spikes.
Side Effects and Safety Profile
Like any glucose-lowering drugs, glinides have a specific spectrum of adverse reactions:
Hypoglycemia: the main side effect. Manifests as tremors, increased sweating, tachycardia, dizziness, general weakness, and a sharp sensation of hunger.
Gastrointestinal and hepatic effects: dyspeptic disorders, abdominal pain, and hepatotoxicity manifested by elevated liver enzymes are possible.
Special senses: transient visual disturbances caused by fluctuations in glycemic levels may occur at the start of therapy.
Allergic manifestations: pruritus, rash, urticaria, and rare changes in the peripheral blood picture.
Mnemonic
Glinides are the sprinters among hypoglycemic agents: 'take 30 minutes before a meal — acts in 15 minutes — catches the sugar spike!'
Frequently asked questions
Which drugs belong to the meglitinide pharmacological group?
The meglitinide (glinide) pharmacological group includes oral hypoglycemic agents that act as prandial glycemic regulators. This group includes the following drugs:
Nateglinide (Starlix) — a phenylalanine amino acid derivative.
Repaglinide — a benzoic acid derivative, which is an analogue of nateglinide.
These drugs are endogenous insulin secretagogues that selectively block potassium channels of pancreatic beta-cells.
What are the contraindications for prescribing meglitinides?
The main contraindications for prescribing meglitinide drugs include the following pathological and physiological conditions:
Renal failure. However, there is an important exception: the use of repaglinide is permissible in this pathology since renal excretion is not its primary route (the drug is excreted mainly via bile).
Hepatic failure.
Ketoacidosis.
Pregnancy and lactation.
What is the main difference in the mechanism of meglitinides compared to sulfonylureas?
Meglitinides have high selectivity for pancreatic channels (300 times higher than for vascular channels) and restore the physiological early phase of insulin secretion. In addition, they act in a glucose-dependent manner: when blood sugar drops, stimulation ceases.
What are the main symptoms of hypoglycemia when taking glinides?
The main symptoms include tremors, sweating, tachycardia, dizziness, general weakness, and a sharp increase in appetite.
Which drug in this group is approved for kidney disease and why?
Repaglinide is approved for patients with renal pathology because its elimination occurs predominantly through the bile, unlike nateglinide, which is excreted renally.
Go deeper
Pleiotropic effects: antioxidant defense and stimulation of alpha-tocopherol synthesis
Metabolic action in tissues via phospholipase C
Pharmacokinetic differences of cytochrome P450 in nateglinide metabolism
Features of repaglinide excretion via the hepatobiliary system
Comparative analysis of transient visual disturbances at the start of therapy